PL2019683T3 - Podawanie czynników wzrostu do leczenia zaburzeń OUN - Google Patents

Podawanie czynników wzrostu do leczenia zaburzeń OUN

Info

Publication number
PL2019683T3
PL2019683T3 PL07761286T PL07761286T PL2019683T3 PL 2019683 T3 PL2019683 T3 PL 2019683T3 PL 07761286 T PL07761286 T PL 07761286T PL 07761286 T PL07761286 T PL 07761286T PL 2019683 T3 PL2019683 T3 PL 2019683T3
Authority
PL
Poland
Prior art keywords
administration
treatment
growth factors
cns disorders
cns
Prior art date
Application number
PL07761286T
Other languages
English (en)
Other versions
PL2019683T5 (pl
Inventor
Krystof S. Bankiewicz
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38656355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2019683(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL2019683T3 publication Critical patent/PL2019683T3/pl
Publication of PL2019683T5 publication Critical patent/PL2019683T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
PL07761286.9T 2006-04-25 2007-04-25 Podawanie czynników wzrostu do leczenia zaburzeń OUN PL2019683T5 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79501206P 2006-04-25 2006-04-25
PCT/US2007/067423 WO2007127803A2 (en) 2006-04-25 2007-04-25 Administration of growth factors for the treatment of cns disorders

Publications (2)

Publication Number Publication Date
PL2019683T3 true PL2019683T3 (pl) 2017-06-30
PL2019683T5 PL2019683T5 (pl) 2022-12-05

Family

ID=38656355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07761286.9T PL2019683T5 (pl) 2006-04-25 2007-04-25 Podawanie czynników wzrostu do leczenia zaburzeń OUN

Country Status (12)

Country Link
US (5) US7922999B2 (pl)
EP (1) EP2019683B2 (pl)
JP (2) JP6105187B2 (pl)
AU (1) AU2007244826B2 (pl)
BR (1) BRPI0710800A2 (pl)
DK (1) DK2019683T4 (pl)
ES (1) ES2618787T5 (pl)
HU (1) HUE030903T2 (pl)
PL (1) PL2019683T5 (pl)
PT (1) PT2019683T (pl)
SI (1) SI2019683T2 (pl)
WO (1) WO2007127803A2 (pl)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4742030B2 (ja) 2003-04-18 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド ポリマーが結合したグリコシル化ニューブラスチン
JP4852545B2 (ja) * 2004-08-19 2012-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
EP2572661B1 (en) 2004-10-05 2019-11-20 Genzyme Corporation Stepped cannula
AU2006283189B2 (en) 2005-08-23 2013-01-31 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
WO2009111649A2 (en) * 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
CA3040377C (en) 2009-10-06 2025-12-30 Yale University Genetically modified mice and engraftment comprising the knock-in of a human thrombopoietin (tpo) gene
EP2558154B1 (en) 2010-04-16 2020-06-17 ClearPoint Neuro, Inc. Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient
US9045751B2 (en) 2010-04-28 2015-06-02 The Regents Of The University Of California Modified small activating RNA molecules and methods of use
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
GB201101167D0 (en) * 2011-01-22 2011-03-09 Renishaw Plc Convection enhanced delivery apparatus and method
ES3040596T3 (en) 2011-02-15 2025-11-03 Regeneron Pharma Humanized m-csf mice and uses thereof
ES2828663T3 (es) 2012-04-18 2021-05-27 Univ Leland Stanford Junior Dirección genética no disruptiva
PL4289948T3 (pl) 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
KR102287541B1 (ko) 2012-09-07 2021-08-10 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
EP4389764B1 (en) 2012-11-05 2026-03-18 Regeneron Pharmaceuticals, Inc. Genetically modified rodents and methods of use thereof
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
WO2014202833A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Treatment of neuronal injuries
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
SG11201707615YA (en) 2013-09-19 2017-10-30 Univ Leland Stanford Junior Methods and compositions for producing hepatocyte-like cells
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
WO2015071474A2 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
CN106460009A (zh) 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
WO2015168666A2 (en) 2014-05-02 2015-11-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
KR20250096864A (ko) 2014-05-19 2025-06-27 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
US10377818B2 (en) 2015-01-30 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Method of treating glioma
NZ772772A (en) 2015-02-10 2024-12-20 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
WO2016154344A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
JP6752221B2 (ja) 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
US10435441B2 (en) 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP3393571B1 (en) 2016-02-17 2024-03-06 ClearPoint Neuro, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
EP3426784A1 (en) 2016-03-11 2019-01-16 Wageningen Universiteit Improved crispr-cpf1 genome editing tool
WO2017155408A1 (en) 2016-03-11 2017-09-14 Erasmus University Medical Center Rotterdam Improved crispr-cas9 genome editing tool
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
KR102674612B1 (ko) 2016-12-01 2024-06-14 상가모 테라퓨틱스, 인코포레이티드 Tau 조절제 및 그것의 전달을 위한 방법 및 조성물
CA3045134A1 (en) 2016-12-14 2018-06-21 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
AU2018272068B2 (en) * 2017-05-25 2025-03-27 Icahn School Of Medicine At Mount Sinai Method and composition for generating basal forebrain cholinergic neurons (BFCNs)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
US20210363521A1 (en) 2017-11-09 2021-11-25 Vertex Pharmaceuticals Incorporated CRISPR/CAS Systems For Treatment of DMD
US11578323B2 (en) 2017-12-14 2023-02-14 Bayer Healthcare Llc RNA-programmable endonuclease systems and their use in genome editing and other applications
WO2019123414A1 (en) 2017-12-22 2019-06-27 Straximm Llp Engineered viruses expressing cyclic gmp-amp synthase
JP2021518160A (ja) 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
AU2019236204B2 (en) 2018-03-15 2026-02-26 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CA3092497A1 (en) 2018-03-19 2019-09-26 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and uses thereof
EP3781074A1 (en) 2018-05-09 2021-02-24 ClearPoint Neuro, Inc. Mri compatible intrabody fluid transfer systems and related devices and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
EP3964210A1 (en) * 2018-05-18 2022-03-09 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease
KR20210075068A (ko) 2018-08-10 2021-06-22 뉴욕 유니버시티 엔젤만 증후군 및 자폐증 치료를 위한 igf-2 수용체 작용제 리간드의 용도
US12491203B2 (en) 2018-08-10 2025-12-09 New York University Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
EP3860618B1 (en) 2018-10-02 2026-02-04 Sangamo Therapeutics, Inc. Compositions for treating tauopathy
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
CN109381488A (zh) * 2018-12-22 2019-02-26 包桂荣 癫痫病的外用药剂及制备方法
WO2020152607A1 (en) 2019-01-22 2020-07-30 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
US12460230B2 (en) 2019-02-10 2025-11-04 The J. David Gladstone Institutes Modified mitochondrion and methods of use thereof
AU2020232029B2 (en) 2019-03-07 2024-03-14 Ilera Therapeutics Llc Formulations for treating cluster symptoms associated with autism spectrum disorder
WO2020209959A1 (en) 2019-03-08 2020-10-15 Crispr Therapeutics Ag Nucleobase-editing fusion protein systems, compositions, and uses thereof
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
PE20212332A1 (es) 2019-04-23 2021-12-14 Sangamo Therapeutics Inc Moduladores de la expresioon del gen de marco de lectura abierto 72 del cromosoma 9 y usos de los mismos
CN110192859B (zh) * 2019-05-05 2020-05-19 兰月 一种磁共振测量人脑类淋巴通路清除效率的方法
EP3966327A1 (en) 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
WO2022258753A1 (en) 2021-06-11 2022-12-15 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
EP4453191A1 (en) 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
EP4536818A1 (en) 2022-06-10 2025-04-16 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
WO2024200573A1 (en) 2023-03-27 2024-10-03 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
KR20260018078A (ko) 2023-05-25 2026-02-06 디스패치 바이오테라퓨틱스, 인크. 암을 치료하기 위한 표적으로서의 합성 암 항원
WO2025004001A1 (en) 2023-06-30 2025-01-02 Takeda Pharmaceutical Company Limited Htt repressors and uses thereof
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37410A (en) 1863-01-13 Improvement in machines for seaming metal roofing
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
CA2119463C (en) 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1148812A (zh) * 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
WO1995028493A1 (en) * 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
JP2001510457A (ja) * 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
CA2303460C (en) * 1997-09-09 2011-06-21 Mariel Therapeutics, Inc. Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors
DE69821629T2 (de) * 1997-09-19 2005-01-13 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Kombinationen von Cytokinen mit neurotroper Aktivität
US6815431B2 (en) * 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7157435B2 (en) * 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
PT1080202E (pt) * 1998-05-27 2006-05-31 Avigen Inc Distribuicao de vectores aav codificando aadc intensificada por conveccao
US7018628B1 (en) * 1998-07-24 2006-03-28 Aventis Pharma S.A. Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
IL162838A0 (en) * 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
AU2003299140B2 (en) 2002-09-24 2008-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20060258576A1 (en) * 2003-09-05 2006-11-16 Licentia, Ltd Gdnf-related neuropeptides
DE602005018043D1 (de) * 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF

Also Published As

Publication number Publication date
WO2007127803A2 (en) 2007-11-08
US20180140672A1 (en) 2018-05-24
PT2019683T (pt) 2017-03-17
JP6190336B2 (ja) 2017-08-30
AU2007244826A1 (en) 2007-11-08
EP2019683A2 (en) 2009-02-04
DK2019683T3 (en) 2017-03-20
EP2019683A4 (en) 2010-08-11
AU2007244826B2 (en) 2013-04-11
EP2019683B2 (en) 2022-08-03
SI2019683T2 (sl) 2022-10-28
WO2007127803A3 (en) 2008-10-23
JP6105187B2 (ja) 2017-03-29
US9724387B2 (en) 2017-08-08
SI2019683T1 (sl) 2017-04-26
US20140017297A1 (en) 2014-01-16
BRPI0710800A2 (pt) 2012-01-17
US8409548B2 (en) 2013-04-02
JP2014224140A (ja) 2014-12-04
EP2019683B1 (en) 2016-12-14
JP2009535359A (ja) 2009-10-01
ES2618787T3 (es) 2017-06-22
US20120009245A1 (en) 2012-01-12
US7922999B2 (en) 2011-04-12
ES2618787T5 (es) 2022-10-21
HUE030903T2 (en) 2017-06-28
PL2019683T5 (pl) 2022-12-05
US20150313962A1 (en) 2015-11-05
DK2019683T4 (da) 2022-08-29
US9050299B2 (en) 2015-06-09
US20070254842A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
SI2019683T1 (sl) Dajanje rastnih faktorjev za zdravljenje motenj CŽS
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
AU2008281877A8 (en) The use of benzamide derivatives for the treatment of CNS disorders
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL192852A0 (en) Compounds for the treatment of metabolic disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
EP1901770A4 (en) METHOD FOR TREATING GROWTH TROUBLESHOOTING
IL198432A0 (en) 2-alkyl-indazole compounds for the treatment of certain cns-related disorders
IL193414A0 (en) Meridamycin analogues for the treatment ofneurodegenererative disorders
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain